Privia Health Group, Inc. (NASDAQ:PRVA) Stake Increased by Nuveen Asset Management LLC

Posted by Defense World Staff on Mar 4th, 2023

Nuveen Asset Management LLC increased its stake in Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) by 55.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 565,534 shares of the company’s stock after buying an additional 202,626 shares during the period. Nuveen Asset Management LLC owned about 0.51% of Privia Health Group worth $19,262,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assetmark Inc. increased its stake in Privia Health Group by 119.4% during the second quarter. Assetmark Inc. now owns 893 shares of the company’s stock valued at $26,000 after purchasing an additional 486 shares during the last quarter. Signaturefd LLC bought a new stake in Privia Health Group during the third quarter valued at $32,000. Nisa Investment Advisors LLC bought a new stake in Privia Health Group during the second quarter valued at $46,000. Point72 Hong Kong Ltd bought a new stake in Privia Health Group during the first quarter valued at $47,000. Finally, Ameritas Investment Partners Inc. increased its stake in Privia Health Group by 111.5% during the first quarter. Ameritas Investment Partners Inc. now owns 3,251 shares of the company’s stock valued at $87,000 after purchasing an additional 1,714 shares during the last quarter. Institutional investors own 66.83% of the company’s stock.

Privia Health Group Stock Up 2.1 %

PRVA stock opened at $28.71 on Friday. The company has a market capitalization of $3.28 billion, a P/E ratio of -261.00, a PEG ratio of 11.29 and a beta of 0.79. The company has a 50-day simple moving average of $25.67 and a 200 day simple moving average of $29.70. Privia Health Group, Inc. has a fifty-two week low of $17.99 and a fifty-two week high of $44.64.

Insider Buying and Selling

In related news, COO Parth Mehrotra sold 53,560 shares of the company’s stock in a transaction dated Tuesday, February 28th. The shares were sold at an average price of $28.13, for a total value of $1,506,642.80. Following the completion of the sale, the chief operating officer now owns 97,391 shares of the company’s stock, valued at $2,739,608.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Privia Health Group news, Director William M. Sullivan sold 6,038 shares of the business’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $25.04, for a total value of $151,191.52. Following the sale, the director now directly owns 5,857,198 shares in the company, valued at $146,664,237.92. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Parth Mehrotra sold 53,560 shares of the business’s stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $28.13, for a total transaction of $1,506,642.80. Following the completion of the sale, the chief operating officer now owns 97,391 shares in the company, valued at $2,739,608.83. The disclosure for this sale can be found here. Insiders sold 168,287 shares of company stock valued at $4,352,843 over the last 90 days. 57.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PRVA has been the subject of several recent research reports. UBS Group initiated coverage on shares of Privia Health Group in a research note on Thursday, December 8th. They set a “buy” rating and a $30.00 target price for the company. Truist Financial lowered their target price on shares of Privia Health Group to $41.00 in a research note on Thursday, November 17th. SVB Leerink reduced their price target on shares of Privia Health Group from $46.00 to $39.00 and set an “outperform” rating for the company in a report on Friday, November 11th. The Goldman Sachs Group assumed coverage on shares of Privia Health Group in a report on Friday, February 3rd. They set a “buy” rating and a $32.00 price target for the company. Finally, Canaccord Genuity Group reduced their price target on shares of Privia Health Group from $50.00 to $43.00 and set a “buy” rating for the company in a report on Friday, November 11th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Privia Health Group presently has a consensus rating of “Buy” and an average target price of $38.93.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.